| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| Ton Schumacher | Q20730283 | ||
| Gemma Kenter | Q37828878 | ||
| Per thor Straten | Q39271505 | ||
| Sine Reker Hadrup | Q42184177 | ||
| Charlotte Albaek | Q55299191 | ||
| John B A G Haanen | Q86605268 | ||
| Joost B Beltman | Q90634356 | ||
| Bianca Heemskerk | Q114017568 | ||
| P2093 | author name string | Paul F Robbins | |
| Mireille Toebes | |||
| Chengyi Jenny Shu | |||
| Yong F Li | |||
| Jacob Schachter | |||
| Mark E Dudley | |||
| Michal J Besser | |||
| Pia Kvistborg | |||
| Carsten Linnemann | |||
| Marit M van Buuren | |||
| Nienke van Rooij | |||
| Manuel Fankhauser | |||
| Jos H M Urbanus | |||
| P2860 | cites work | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens | Q24644442 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 | Q29616128 | ||
| Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases | Q33788932 | ||
| Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients | Q34111120 | ||
| CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma | Q34299986 | ||
| The human T cell response to melanoma antigens | Q34587175 | ||
| Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy | Q34823783 | ||
| Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. | Q34988072 | ||
| Exome sequencing identifies GRIN2A as frequently mutated in melanoma | Q35179796 | ||
| Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes | Q36327157 | ||
| Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers | Q36403280 | ||
| Human T cell responses against melanoma | Q36427328 | ||
| HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides | Q36954248 | ||
| Design and analysis issues in genome-wide somatic mutation studies of cancer | Q37240379 | ||
| Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma | Q37394755 | ||
| Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections | Q37474904 | ||
| Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety | Q40042339 | ||
| Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation | Q45370775 | ||
| Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. | Q46128909 | ||
| Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation | Q46594776 | ||
| Epitope landscape in breast and colorectal cancer. | Q51894674 | ||
| Design and use of conditional MHC class I ligands. | Q53637625 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 409-418 | |
| P577 | publication date | 2012-07-01 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients | |
| P478 | volume | 1 |
| Q38237522 | Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? |
| Q34350259 | Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma |
| Q38753404 | Adoptive T-Cell Therapy for Cancer |
| Q38525029 | Adoptive T-cell therapy: a need for standard immune monitoring. |
| Q36444798 | Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients |
| Q57038247 | Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option |
| Q38783946 | Advances in personalized cancer immunotherapy. |
| Q38049010 | Advances in the development of cancer immunotherapies |
| Q42186944 | Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. |
| Q64264461 | Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients |
| Q38784018 | Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy |
| Q93052202 | Apparent Lack of BRAF V600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis |
| Q42417533 | BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer |
| Q40964128 | Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab |
| Q35546276 | Broadening the repertoire of melanoma-associated T-cell epitopes. |
| Q34044213 | CAR-modified T-cell therapy for cancer: an updated review. |
| Q89556582 | CD8+ T cell states in human cancer: insights from single-cell analysis |
| Q34788858 | Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens |
| Q90419584 | Current Perspectives in Cancer Immunotherapy |
| Q38953021 | Current tools for predicting cancer-specific T cell immunity |
| Q36694942 | Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients |
| Q57201489 | Determining T-cell specificity to understand and treat disease |
| Q42952683 | Effector CD4 and CD8 T cells and their role in the tumor microenvironment |
| Q39093439 | Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients |
| Q37576033 | Exploiting the curative potential of adoptive T-cell therapy for cancer |
| Q27026627 | Genetically modified T cells in cancer therapy: opportunities and challenges |
| Q35117552 | Going back to class I: MHC and immunotherapies for childhood cancer. |
| Q41918189 | Guidelines for the use of flow cytometry and cell sorting in immunological studies |
| Q34985471 | HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). |
| Q37582737 | High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies |
| Q38926293 | High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma |
| Q35016476 | High-throughput identification of antigen-specific TCRs by TCR gene capture |
| Q89457615 | Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma |
| Q36694896 | Immune correlates of melanoma survival in adoptive cell therapy |
| Q42362520 | Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma |
| Q56897379 | Immunotherapy of melanoma |
| Q47290509 | Informatics for cancer immunotherapy |
| Q92334561 | Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer |
| Q40242985 | Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer |
| Q90228169 | Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers |
| Q95841152 | Measuring Intratumoral Heterogeneity of Immune Repertoires |
| Q30621114 | Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells |
| Q97644519 | Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal |
| Q34470074 | Neoantigens in cancer immunotherapy. |
| Q38646138 | Novel Treatments in Development for Melanoma. |
| Q26770780 | Novel technologies and emerging biomarkers for personalized cancer immunotherapy |
| Q37726682 | PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors |
| Q60634938 | Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers |
| Q38665128 | Predictors of tumor-infiltrating lymphocyte efficacy in melanoma |
| Q40355238 | Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab |
| Q91982102 | Prospect of Plasmacytoid Dendritic Cells in Enhancing Anti-Tumor Immunity of Oncolytic Herpes Viruses |
| Q98280952 | Reversal of pre-existing NGFR-driven tumor and immune therapy resistance |
| Q61807041 | Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer |
| Q34003592 | Shaping the repertoire of tumor-infiltrating effector and regulatory T cells |
| Q38860651 | Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma |
| Q52596337 | T Cell Dysfunction in Cancer. |
| Q38376433 | T cell receptor repertoire usage in cancer as a surrogate marker for immune responses |
| Q92245345 | T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance |
| Q52689465 | T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology. |
| Q42333881 | T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy |
| Q42169344 | TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination |
| Q38170497 | TCR repertoires of intratumoral T-cell subsets |
| Q36618620 | Targeting human melanoma neoantigens by T cell receptor gene therapy |
| Q64244225 | Th17 Cells Paradoxical Roles in Melanoma and Potential Application in Immunotherapy |
| Q41442041 | The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies |
| Q98178302 | The High Level of Tertiary Lymphoid Structure Is Correlated With Superior Survival in Patients With Advanced Gastric Cancer |
| Q38753386 | The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer |
| Q41475076 | The antigen specific composition of melanoma tumor infiltrating lymphocytes? |
| Q36710982 | The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity |
| Q38069075 | The cancer antigenome |
| Q48360550 | Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8+ T-cell immunity. |
| Q38203472 | Tumor antigen discovery through translation of the cancer genome |
| Q42874163 | Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma |
| Q37320131 | Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. |
| Q38636573 | Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. |
Search more.